Allan Jonathan sold $44K of STOK
Allan Jonathan (GENERAL COUNSEL & CORP SEC) sold 1,457 shares of Stoke Therapeutics, Inc. (STOK) at $29.95 on 2026-06-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and total value, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the disclosed insider sale, but the 10b5-1 framing reduces the likelihood of a strong fundamental interpretation.
What to watch
The article does not disclose whether other insiders sold/bought, nor does it provide total insider ownership changes beyond the post-transaction share count.
Background
This is an SEC Form 4 insider transaction disclosure for Stoke Therapeutics, Inc. (STOK).
Ticker impact
Stoke Therapeutics Form 4 shows General Counsel Allan Jonathan sold 1,457 shares at $29.95 on a 10b5-1 plan, totaling $43,637.15.
Low near-term impact; any reaction is likely muted unless accompanied by other company-specific news.
The filing is a disclosed open-market sale under a pre-arranged Rule 10b5-1 plan, with no indication of distress, new guidance, or operational change in the text.
Market effects
No sector read-through is provided beyond a single routine insider transaction.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can still be interpreted by some traders as a gradual de-risking signal.
Key entities
- issuerStoke Therapeutics, Inc.
Company whose insider transaction is disclosed on Form 4.
- insiderAllan Jonathan
General Counsel and corporate secretary who sold shares.
